| Kymera Therapeutics Unveils IPO Pitch for Protein Degradation | Frank Vinluan | 07/31/20 | Boston |
| Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More | Frank Vinluan | 07/31/20 | National |
| Novartis Pays $75M to Get Hands on Sangamo’s Zinc Fingers for Drug R&D | Sarah de Crescenzo | 07/30/20 | San Francisco |
| Roche Pays $120M for Rights to UCB’s Tau-Targeting Alzheimer’s Drug | Frank Vinluan | 07/29/20 | Europe |
| Nura Bio Debuts With $73M and Plan to Develop “Neuroprotective” Drugs | Sarah de Crescenzo | 07/29/20 | San Francisco |
| Thrive Adds $257M, Plans Pivotal Trial of Early Cancer Detection Test | Sarah de Crescenzo | 07/29/20 | National |
| Gilead Gets Another CAR-T Approval, This Time for Mantle Cell Lymphoma | Frank Vinluan | 07/24/20 | San Francisco |
| Bio Roundup: Jazz Drug OK’d, Gilead’s Bet, Moderna Patent Decision & More | Sarah de Crescenzo | 07/24/20 | National |
| FDA Lifts CymaBay Drug Hold, Tests to Resume in Rare Liver Disease PBC | Frank Vinluan | 07/23/20 | San Francisco |
| Jazz Pharma Gets FDA Nod for New Drug to Treat Narcolepsy Symptoms | Sarah de Crescenzo | 07/22/20 | Europe |
| Seer Raises $55M to Commercialize Tools to Analyze the Proteome | Sarah de Crescenzo | 07/22/20 | San Francisco |
| Olema Adds $54M to Start Human Tests of Breast Cancer Drug Candidate | Sarah de Crescenzo | 07/22/20 | San Francisco |
| Gilead Sciences Splashes Out $300M for Tizona Stake & Option to Acquire | Sarah de Crescenzo | 07/21/20 | San Francisco |
| Exalys Launches With $15M to Treat Postoperative Delirium & More | Sarah de Crescenzo | 07/17/20 | San Diego |
| Two Days, Six IPOs, and $1B Raised for Biotech Research & More | Frank Vinluan | 07/17/20 | National |
| Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More | Frank Vinluan | 07/17/20 | National |
| Last Chance for Xconomy Awards Nominations – Deadline is Friday, July 17 | Editors | 07/15/20 | Boston |
| Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact | Frank Vinluan | 07/14/20 | Boston |
| Amgen Doubles Down on BeiGene Collaboration, Investing $421M More | Sarah de Crescenzo | 07/13/20 | San Francisco |
| 3 Biotech IPOs Together Rake In Over a Half Billion to Advance Treatments | Sarah de Crescenzo | 07/13/20 | National |
| Bio Roundup: Blackstone’s Billions, Biogen Finishes Filing, Novavax at “Warp Speed” & More | Sarah de Crescenzo | 07/10/20 | National |
| VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs | Sarah de Crescenzo | 07/09/20 | San Diego |
| Novavax Gets $1.6B in Operation Warp Speed Funding for COVID-19 Vaccine | Sarah de Crescenzo | 07/07/20 | National |
| PacBio CEO, CFO Plan Retirements and More People on the Move | Editors | 07/07/20 | National |
| On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO | Sarah de Crescenzo | 07/06/20 | San Francisco |
| Moderna: Speed of COVID 19 Vaccine Hinges On Enrolling Right Patients | Sarah Karlin-Smith | 07/02/20 | National |
| Data Quantity, Complexity Drives Use of AI in Drug Discovery and Testing | Frank Vinluan | 07/02/20 | San Francisco |
| Annexon Adds On $100M to Advance Antibodies to Treat Neurodegeneration | Sarah de Crescenzo | 07/01/20 | San Francisco |
| Bolt Bio Adds $93.5M to Move Ahead Immune-Stimulating Cancer Drugs | Sarah de Crescenzo | 07/01/20 | San Francisco |
| Ultragenyx Pharma Wins FDA’s First Drug Nod for Rare Metabolic Disorder | Frank Vinluan | 06/30/20 | San Francisco |
